Genomics|Update|Non Communicable Diseases ► Cancer

Genomics|Update|Non Communicable Diseases

Volume 34  Number 15  April 16-23, 2015

Cancer

A decision support framework for genomically informed investigational cancer therapy. 
Meric-Bernstam F et al. J. Natl. Cancer Inst. 2015 Jul 107(7)

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. 
Rebbeck TR et al. JAMA 2015 Apr 7. 313(13) 1347-61

Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. 
Sutton EJ et al. J Magn Reson Imaging 2015 Apr 7.

Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.Hinrichs JW J et al. Am. J. Clin. Pathol. 2015 Apr 143(4) 573-8

Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. 
Jagsi R et al. J. Clin. Oncol. 2015 Apr 6.

Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality. 
Ponce NA et al. Health Aff (Millwood) 2015 Apr 1. 34(4) 609-15

Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. 
Cragun D et al. Breast Cancer Res. Treat. 2015 Apr 14.

Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer. 
Cremers RG et al. Prostate 2015 Apr 1. 75(5) 474-83

On the road to precision cancer medicine: Analysis of genomic biomarker actionability in 439 patients. 
Schwaederle M et al. Mol. Cancer Ther. 2015 Apr 7.

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire. 
Yang D et al. World J. Gastroenterol. 2014 May 7. 20(17) 4972-9

Prediction of breast cancer risk based on profiling with common genetic variants. 
Mavaddat N et al. J. Natl. Cancer Inst. 2015 May 107(5)

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer. 
Martín M et al. Curr Med Res Opin 2015 Apr 8. 1-28

Randomized trial of telegenetics vs. in-person cancer genetic counseling: Cost, patient satisfaction and attendance. 
Buchanan AH et al. J Genet Couns 2015 Apr 3.

Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators
Schneider JL, et al. Genetics in Medicine (2015) April 16

The contributions of breast density and common genetic variation to breast cancer risk. 
Vachon CM et al. J. Natl. Cancer Inst. 2015 May 107(5)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. 
Fitzal F et al. Br. J. Cancer 2015 Apr 14. 112(8) 1405-1410

The sooner the better: Genetic testing following ovarian cancer diagnosis. 
Fox E et al. Gynecol. Oncol. 2015 Apr 10.

The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. 
Bancroft EK et al. Psychooncology 2015 Apr 14.